Auxilium Pharmaceuticals Inc

Auxilium Pharmaceuticals — Q3 2014 Earnings Presentation

26 slides from Auxilium Pharmaceuticals's earnings presentation, Nov 5, 2014

  1. Slide 1: Rule 425 filing cover note

    Filed by Endo International plc (Commission File No. 001-36326) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Auxilium Pharmaceuticals, Inc. (Commission File No. 001-36628) The following slide

  2. Slide 2: Endo International plc Q3 2014 Earnings Report

    Endo International plc Q3 2014 Earnings Report November 5, 2014 ©2014 Endo Pharmaceuticals Inc. All rights reserved.

  3. Slide 3: Additional Information

    Additional Information ADDITIONAL INFORMATION This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. This communication relates to a proposed business combination transaction between Endo International plc ("Endo") and Auxilium Pharmaceuticals, Inc

  4. Slide 4: Forward Looking Statements; Non-GAAP Financial Measures

    Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. Statements including words such as “believes,”“expects,”“anticipates,”“intends

  5. Slide 5: Today's Agenda

    Today’s Agenda Review of Recent Accomplishments Review of Q3 2014 Financial Results Update to 2014 Financial Guidance Q&A 3 ©2014 Endo Pharmaceuticals Inc. All rights reserved.

  6. Slide 6: Progress on Near-Term Strategic Priorities

    Progress on Near-Term Strategic Priorities Deploying capital to accretive, value-creating opportunities • Announced agreement to acquire Auxilium Pharmaceuticals • Closed acquisitions of Grupo Farmaceutico Somar and DAVA Pharmaceuticals Enhancing operational focus on organic growth drivers • Deliver

  7. Slide 7: Endo to Acquire Auxilium - Transaction Summary

    Endoto AcquireAuxilium- TransactionSummary Creates leading specialty healthcare company with expanded platform for future growth Significant opportunity for value creation Expected to be immediately accretive post-close and substantially accretive long-term Base-case exceeds key M&A model hurdle rat

  8. Slide 8: Compelling Strategic and Financial Rationale

    Compelling Strategic and Financial Rationale Expected to significantly enhance Endo's branded pharmaceutical business with the addition of Auxilium's leading men's health products and development portfolio Designed to accelerate growth and maximize value of Auxilium’s products by leveraging strength

  9. Slide 9: Summary of Q3 2014 Financial Results and Organic Growth

    Summary of Q3 2014 Financial Results and Organic Growth ©2014 Endo Pharmaceuticals Inc. All rights reserved.

  10. Slide 10: Q3 and YTD 2014 Financial Performance

    Q3 and YTD 2014 Financial Performance (US $M except EPS) Y/Y Y/Y Q3 2014 YTD 2014 Growth % Growth % Revenue $764 16% $2,077 2% Reported (GAAP) EPS ($1.64) NM ($4.62) NM Adjusted Net Income $182 13% $490 9% Adjusted Diluted EPS $1.15 (14%) $3.14 (18%) 8 ©2014 Endo Pharmaceuticals Inc. All rights rese

  11. Slide 11: Drive Organic Growth – U.S. Branded Pharmaceuticals

    DriveOrganicGrowth– U.S.BrandedPharmaceuticals U.S. Branded Pharmaceuticals Core portfolio of products on- Core Revenue Growth vs. PY track to deliver 2014 objective for 11% growth Expect to submit NDA for BEMA® 6% buprenorphine by end of 2014 or early 2015 Successful management of LIDODERM LOE YTD

  12. Slide 12: Drive Organic Growth – U.S. Generic Pharmaceuticals

    DriveOrganicGrowth– U.S.GenericPharmaceuticals U.S. Generic Pharmaceuticals Base business growth of 13% in Q3 Q3 Core Revenue Growth vs. PY 2014 74% $111m of new revenues in Q3 2014 drive total revenue growth of 74% for U.S. Generics Continued success for Lidoderm AG 13% launch Acquisitions of Boca

  13. Slide 13: Drive Organic Growth – Devices

    DriveOrganicGrowth- Devices Devices Revenue Growth Versus Prior Year On-track to return to organic revenue growth and expand 2% 2% operating margins BPH Therapy business leading TM growth assalesof GreenLight fiber continue to increase ~Flat Men’s Health business provides stable/growing core Managin

  14. Slide 14: Drive Organic Growth – International Pharmaceuticals

    Drive Organic Growth International – Pharmaceuticals 2014 performance on-track with internal expectations Paladin business development continues to add future growth drivers Launches of Travelan® and Veregen®in Canada Base Paladin business delivering solid performance Integration of Somar on-track N

  15. Slide 15: Q3 2014 Financial Update and Full-Year Guidance

    Q3 2014 Financial Update and Full-Year Guidance ©2014 Endo Pharmaceuticals Inc. All rights reserved.

  16. Slide 16: Q3 and YTD 2014 Segment Revenues

    Q3 and YTD 2014 Segment Revenues (US $M) Y/Y Y/Y Q3 2014 YTD 2014 Growth % Growth % U.S. Branded Pharmaceuticals $241 (34%) $724 (36%) U.S. Generic Pharmaceuticals $319 74% $803 51% Devices $110 (1%) $359 ~Flat International Pharmaceuticals $94 NM $191 NM Total $764 16% $2,077 2% 14 ©2014 Endo Pharm

  17. Slide 17: Q3 and YTD 2014 Income Statement (Adjusted)

    Q3 and YTD 2014 Income Statement (Adjusted) ($M except Shares and EPS) Y/Y Change Y/Y Change Q3 2013 Q3 2014 Favorable / YTD 2013 YTD 2014 Favorable / (Unfavorable) (Unfavorable) Revenues $661 $764 16% $2,032 $2,077 2% Gross Margin $448 $479 7% $1,389 $1,336 (4%) % of Revenues 67.7% 62.8% 68.4% 64.3

  18. Slide 18: 2014 Financial Guidance

    2014 Financial Guidance Measure Prior Guidance Updated 2014 Guidance Revenues $2.78B -$2.86B $2.80B -$2.88B Adjusted Gross Margin 63% to 65% 63.5% to 64.5% Adjusted Operating Year-over-year mid-to-high digit Year-over-year mid-to-high digit Expenses percentage decrease percentage decrease Adjusted I

  19. Slide 19: Progress on Near-Term Strategic Priorities

    Progress on Near-Term Strategic Priorities Deploying capital to accretive, value-creating opportunities • Announced agreement to acquire Auxilium Pharmaceuticals • Closed acquisitions of Grupo Farmaceutico Somar and DAVA Pharmaceuticals Enhancing operational focus on organic growth drivers • Deliver

  20. Slide 20: Appendix

    Appendix ©2014 Endo Pharmaceuticals Inc. All rights reserved.

  21. Slide 21: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures Actual Notes to reconciliation of our GAAP statements of operations to our Three Months Ended September 30, 2014 Reported Non-GAAP adjusted statements of operations: (unaudited) (GAAP) Adjustments Adjusted 1. To exclude amortization of commercial intangible assets

  22. Slide 22: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures Actual Notes to reconciliation of our GAAP statements of operations to our Three Months Ended September 30, 2013 Reported Non-GAAP adjusted statements of operations: (unaudited) (GAAP) Adjustments Adjusted REVENUES $ 661,319 $ — $ 661,319 1. To exclude amortizatio

  23. Slide 23: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures Notes to reconciliation of our GAAP statements of operations to our adjusted Actual Nine Months Ended September 30, 2014 statements of operations: Reported Non-GAAP (unaudited) (GAAP) Adjustments Adjusted 1. To exclude amortization of commercial intangible assets

  24. Slide 24: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures Notes to reconciliation of our GAAP statements of operations to our adjusted Actual statements of operations: Nine Months Ended September 30, 2013 Reported Non-GAAP (unaudited) (GAAP) Adjustments Adjusted 1. To exclude amortization of commercial intangible assets

  25. Slide 25: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures For an explanation of Endo’s reasons for using non-GAAP measures, see Endo’s Current Report on Form 8-K filed today with the Securities and Exchange Commission Reconciliation of Projected GAAP Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share Guida

  26. Slide 26: Endo International plc Q3 2014 Earnings Report

    Endo International plc Q3 2014 Earnings Report November 5, 2014 ©2014 Endo Pharmaceuticals Inc. All rights reserved.

Auxilium Pharmaceuticals — Q3 2014 Earnings Presentation on 6ix